<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab1">
 <label>Table 28.1</label>
 <caption>
  <p>The most common assays along with their advantage and disadvantages</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th/>
    <th>Advantages</th>
    <th>Disadvantages</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="6">Genotypic assays</td>
    <td>Rapid turnaround time (days versus week)</td>
    <td>Measurement of drug resistance is indirect – identified mutations are subjectively translated into conclusions on viral resistance</td>
   </tr>
   <tr>
    <td>Reduced cost</td>
    <td>Only identifies mutations in predominant viral quasispecies (&lt;25 % of viral population)</td>
   </tr>
   <tr>
    <td>Proven utility in the predicting short-term virologic outcome</td>
    <td>Unclear relevance of certain mutations</td>
   </tr>
   <tr>
    <td>Allow detection of emerging mutations before onset of resistance</td>
    <td>Drug resistance does not correlate with mutations in all cases</td>
   </tr>
   <tr>
    <td>Detect contamination between specimens</td>
    <td>Interpretation can be difficult when multiple mutations are present</td>
   </tr>
   <tr>
    <td>Simple technology, available in regular hospital laboratories</td>
    <td>Unable to detect mutation linkage</td>
   </tr>
   <tr>
    <td rowspan="5">Phenotypic assays</td>
    <td>Directly measure drug susceptibility: determine IC50 or IC90 (contamination of drug required to inhibit viral replication by 50 or 90 %)</td>
    <td>Nonstandarized cutoff values</td>
   </tr>
   <tr>
    <td>Measure susceptibility to any drug, determine the presence of cross-resistance and multidrug resistance</td>
    <td>Only identifies mutations in predominant viral quasispecies (&lt;25 % of viral population)</td>
   </tr>
   <tr>
    <td>Measure overall effect of mutations, can assess non-B-clade HIV-1 strains and potential to measure viral tropism and replication capacity in parallel</td>
    <td>Long-term drug response cannot be determined, fails to account for interaction between drugs in combination therapy</td>
   </tr>
   <tr>
    <td rowspan="2">Straightforward interpretation</td>
    <td>Highly complex testing platform with longer turnaround time</td>
   </tr>
   <tr>
    <td>Increased cost</td>
   </tr>
   <tr>
    <td rowspan="4">Virtual phenotype</td>
    <td>Pattern-matching algorithm that uses a large genotypic–phenotypic correlative database to infer phenotypic properties based on sequence data</td>
    <td>It is not known which mutations are used to match a new sequence to those sequences that are already in the database</td>
   </tr>
   <tr>
    <td>Includes a tabulation of the number of matches in the database for each drug and the distribution of phenotypes (fold increase in IC50) for the matching sample</td>
    <td>Its predictive power depends on the number of matched data sets available. Thus, variation is frequently higher in smaller data sets, as well as for newer drugs or complex resistant patterns</td>
   </tr>
   <tr>
    <td>Provides a quantitative prediction of drug resistance</td>
    <td rowspan="2">Matches are based on preselected codons, not on the entire nucleotide sequence</td>
   </tr>
   <tr>
    <td>Showed good correlation for most drugs</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
